Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LAILA A HASSAN

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1942395496
CMS profile
133077
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$1,408.73

70 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,377.41 69
Education $31.32 1

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–70 of 70 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LAILA A HASSAN

NPI 1942395496 · CMS profile ID 133077

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–70 of 70 matching records. This page contains 20 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1942395496?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LAILA A HASSAN, NPI 1942395496, CMS profile ID 133077. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–70 of 70 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1942395496?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). LAILA A HASSAN, NPI 1942395496, CMS profile ID 133077. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–70 of 70 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1942395496?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
LAILA A HASSAN, NPI 1942395496, CMS profile ID 133077, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–70 of 70 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1942395496?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

70 matching records · $1,408.73 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 70 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–70 of 70.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Corcept Therapeutics $28.6203/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214249642 CMS
Novo Nordisk Inc $23.9403/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189166083 CMS
E.R. Squibb & Sons, L.L.C. $20.7603/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184933243 CMS
ABBVIE INC. $13.3003/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202017746 CMS
Bayer Healthcare Pharmaceuticals Inc. $24.8603/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225569808 CMS
Pacira Pharmaceuticals Incorporated $17.5003/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250278478 CMS
AstraZeneca Pharmaceuticals LP $72.2502/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207031581 CMS
Novo Nordisk Inc $24.3402/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188677643 CMS
E.R. Squibb & Sons, L.L.C. $6.7802/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184933223 CMS
E.R. Squibb & Sons, L.L.C. $20.0202/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184933227 CMS
AstraZeneca Pharmaceuticals LP $20.1602/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207019486 CMS
PFIZER INC. $28.2802/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231631653 CMS
ABBVIE INC. $24.4501/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202017744 CMS
ABBVIE INC. $7.5701/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202017742 CMS
ABBVIE INC. $23.0201/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202017740 CMS
Novo Nordisk Inc $18.1801/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188614354 CMS
Amneal Pharmaceuticals LLC $15.6801/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1220536029 CMS
E.R. Squibb & Sons, L.L.C. $2.5501/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184933211 CMS
ABBVIE INC. $22.5001/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202017738 CMS
Amgen Inc. $10.3401/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227245124 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,429.91 102
PY2020 $2,200.80 60
PY2021 $1,475.67 76
PY2022 $916.21 50
PY2023 $1,712.78 74
PY2024 $1,944.62 80
PY2025 $1,408.73 70

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $200,529.77 31
PY2024 Recipient $1,706.46 2
PY2024 Principal investigator $98,885.93 13
PY2023 Recipient $3,630.16 1
PY2023 Principal investigator $81,070.51 10
PY2022 Recipient $46.00 1
PY2022 Principal investigator $31,750.25 9
PY2021 Principal investigator $165,204.17 38
PY2020 Recipient $338.50 2
PY2020 Principal investigator $115,730.42 24
PY2019 Recipient $4,034.00 1
PY2019 Principal investigator $164,808.17 19

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

31 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,076.32 12/17/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LL
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223289892
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,645.16 12/01/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LL
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223289122
Principal investigator 1 ABBVIE INC. $1,750.00 11/26/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202525464
Principal investigator 1 ABBVIE INC. $1,216.00 11/25/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202525326
Principal investigator 1 ABBVIE INC. $2,600.00 10/22/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202518133
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,925.63 10/15/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LL
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223286999
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,038.13 10/01/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LL
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223286153
Principal investigator 1 ABBVIE INC. $2,520.00 09/18/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202511342
Principal investigator 1 ABBVIE INC. $1,365.00 09/16/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202510992
Principal investigator 1 ABBVIE INC. $6,000.00 09/01/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202506657
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,398.97 08/20/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223284387
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,854.14 08/01/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223283425
Principal investigator 1 Eli Lilly and Company $20,378.00 07/28/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC INC RESEARCH CENTER
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187876117
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,294.92 07/18/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223282796
Principal investigator 1 ABBVIE INC. $5,000.00 07/01/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202493719
Principal investigator 1 ABBVIE INC. $14,500.00 06/03/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202488425
Principal investigator 1 ABBVIE INC. $1,800.00 05/07/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202483375
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $609.96 05/02/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223278868
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,000.00 04/18/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223278532
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,750.00 04/02/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223277466
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 04/02/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223277468
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 04/02/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223277470
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,500.00 04/02/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223277546
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 04/02/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223277548
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $600.00 02/21/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223275487
Principal investigator 1 Eli Lilly and Company $30.60 02/10/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC INC RESEARCH CENTER
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187876119
Principal investigator 1 Eli Lilly and Company $3,387.94 01/27/2025 Non-covered Recipient Entity
DR AMIR HASSAN
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187881368
Principal investigator 1 Eli Lilly and Company $66,534.00 01/21/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC INC RESEARCH CENTER
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187875475
Principal investigator 1 Eli Lilly and Company $5,087.00 01/21/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC INC RESEARCH CENTER
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187875477
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 01/15/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223273937
Principal investigator 1 Eli Lilly and Company $5,168.00 01/06/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC INC RESEARCH CENTER
A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187877069